Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DDMAC Dislike: FDA Cracks Down On Facebook Widget Used On Tasigna Website

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency says Novartis' "Facebook Share" items, which users can post on their Facebook walls, must include risk along with efficacy information.
Advertisement

Related Content

Social Media Monitoring: The Next Frontier In Corp. Integrity Agreements?
AstraZeneca Pulls Twitter Ads, Showing Risks Of Expansive Social Media Platforms
Socially Adept: Pharma Companies Must Proactively Gauge Risk Tolerance For Online Promotions, Experts Advise
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
FDA's Internet Promotion Policy: Christmas Cards In Lieu Of Guidance?
FDA's Internet Promotion Guidance: One Down By Year-End; Four More To Go?
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA Social Media Group Reviewing Its First iPhone App As DTC Marketing Tool, But It's Not The First To Be Released
Google Creates New Formats To Include Risk Information In Sponsored Search Results
Google Creates New Formats To Include Risk Information In Sponsored Search Results

Topics

Advertisement
UsernamePublicRestriction

Register

PS071132

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel